中国医药
(600056)
| 流通市值：132.34亿 | | | 总市值：132.39亿 |
| 流通股本：14.95亿 | | | 总股本：14.96亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 16,951,924,948.17 | 8,188,780,055.69 | 35,361,621,734.95 | 25,894,435,068.47 |
| 营业总成本 | 16,372,550,315.06 | 7,879,789,178.24 | 34,112,387,650.65 | 24,983,221,781.2 |
| 其他经营收益 | | | | |
| 营业利润 | 477,896,057.56 | 312,740,001.63 | 1,022,988,204.38 | 823,762,646.19 |
| 利润总额 | 480,338,220.38 | 314,307,790.51 | 999,294,796.62 | 822,447,705.46 |
| 净利润 | 312,220,347.57 | 237,139,518.53 | 674,635,843.84 | 588,710,745.06 |
| 每股收益 | | | | |
| 其他综合收益 | 573,922.49 | -1,525,891.19 | -8,387,833.07 | 613,986.04 |
| 综合收益总额 | 312,794,270.06 | 235,613,627.34 | 666,248,010.77 | 589,324,731.1 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 29,591,414,444.12 | 28,279,869,560.68 | 28,079,061,522.76 | 28,050,937,670.53 |
| 非流动资产: | | | | |
| 非流动资产合计 | 9,353,218,759.3 | 9,197,387,971.61 | 8,791,908,285.01 | 8,936,647,655.78 |
| 资产总计 | 38,944,633,203.42 | 37,477,257,532.29 | 36,870,969,807.77 | 36,987,585,326.31 |
| 流动负债: | | | | |
| 流动负债合计 | 20,446,966,002.17 | 19,873,929,214.34 | 19,725,513,963.7 | 19,648,179,014.1 |
| 非流动负债: | | | | |
| 非流动负债合计 | 3,966,467,744.46 | 3,002,547,891.92 | 2,781,857,172.81 | 3,048,501,112.7 |
| 负债合计 | 24,413,433,746.63 | 22,876,477,106.26 | 22,507,371,136.51 | 22,696,680,126.8 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 11,973,367,900.45 | 12,018,004,410.41 | 11,835,948,719.71 | 11,852,956,503.47 |
| 股东权益合计 | 14,531,199,456.79 | 14,600,780,426.03 | 14,363,598,671.26 | 14,290,905,199.51 |
| 负债和股东权益合计 | 38,944,633,203.42 | 37,477,257,532.29 | 36,870,969,807.77 | 36,987,585,326.31 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 16,860,228,897.43 | 7,369,571,599.36 | 37,405,266,841.25 | 26,276,960,397.43 |
| 经营活动现金流出小计 | 17,722,981,785.01 | 8,790,891,698.65 | 35,979,387,562.23 | 26,589,498,198.44 |
| 经营活动产生的现金流量净额 | -862,752,887.58 | -1,421,320,099.29 | 1,425,879,279.02 | -312,537,801.01 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 18,638,297 | 15,386,966 | 40,349,363.18 | 27,940,922.39 |
| 投资活动现金流出小计 | 443,587,341.14 | 410,952,589.83 | 339,956,644.42 | 213,772,988.8 |
| 投资活动产生的现金流量净额 | -424,949,044.14 | -395,565,623.83 | -299,607,281.24 | -185,832,066.41 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 3,443,500,840.04 | 1,255,193,949.95 | 6,504,330,076.46 | 3,427,503,979.32 |
| 筹资活动现金流出小计 | 2,670,221,140.85 | 1,174,008,392.73 | 8,108,643,218.95 | 4,543,313,803.72 |
| 筹资活动产生的现金流量净额 | 773,279,699.19 | 81,185,557.22 | -1,604,313,142.49 | -1,115,809,824.4 |
| 汇率变动对现金及现金等价物的影响 | -2,259,883.42 | -110,384.4 | -12,441,591 | -4,976,557.26 |
| 现金及现金等价物净增加额 | -516,682,115.95 | -1,735,810,550.3 | -490,482,735.71 | -1,619,156,249.08 |
| 期末现金及现金等价物余额 | 2,833,203,591.72 | 1,614,075,157.37 | 3,349,885,707.67 | 2,237,993,441.39 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -516,682,115.95 | - | -490,482,735.71 | - |